Lisata Therapeutics Inc (LSTA)

Currency in USD
1.4500
-0.0300(-2.03%)
Real-time Data·
LSTA is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
1.40001.5000
52 wk Range
0.98755.0700
Key Statistics
Prev. Close
1.48
Open
1.46
Day's Range
1.4-1.5
52 wk Range
0.9875-5.07
Volume
70.73K
Average Volume (3m)
287.48K
1-Year Change
-36.6812%
Book Value / Share
0.91
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
LSTA Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
0.0000
Downside
-100.00%
Members' Sentiments
Bearish
Bullish
ProTips
Quickly burning through cash

Lisata Therapeutics Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Sell

Analyst Ratings

0 Buy
2 Hold
0 Sell
Ratings:
2 analysts
Overall Consensus
Neutral

Analysts 12-Month Price Target:

Average 0.0000
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Brookline Capital Markets
Hold---DowngradeJul 27, 2026
H.C. Wainwright
Hold---DowngradeMay 15, 2026
Brookline Capital Markets
Hold---DowngradeJan 21, 2026

Lisata Therapeutics Inc Earnings Call Summary for Q3/2025

  • Lisata Therapeutics reported Q3 2025 EPS of -$0.49, beating analyst expectations of -$0.59, but stock fell 7.26% in aftermarket trading to $2.17.
  • Operating expenses decreased 17.3% year-over-year to $4.4 million, with R&D expenses down 22.9% and net losses reduced to $4.2 million from $4.9 million.
  • Despite positive earnings surprise of 16.95%, investor concerns persist about ongoing net losses and the company's ability to secure funding for future trials.
  • Management anticipates upcoming phase 3 trials for sirtepotide and is focused on securing pharmaceutical partnerships to fund clinical programs.
  • CEO Dr. David Mazzo highlighted positive results across various studies, while CMO Dr. Kristen Buck emphasized sirtepotide's ability to modify tumor microenvironments.
Last Updated: 06/11/2025, 23:50
Read Full Transcript

Earnings

Latest Release
Aug 31, 2026
EPS / Forecast
-0.32 / --
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

LSTA Income Statement

Compare LSTA to Peers and Sector

Metrics to compare
LSTA
Peers
Sector
Relationship
P/E Ratio
−0.9x−1.7x−0.4x
PEG Ratio
−0.03−0.060.00
Price/Book
1.5x1.5x2.6x
Price / LTM Sales
126.2x5.8x3.1x
Upside (Analyst Target)
170.3%230.8%52.9%
Fair Value Upside
Unlock20.4%6.4%Unlock

Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product is certepetide, which is in Phase 2 clinical studies for the treatment of solid tumors, such as metastatic pancreatic ductal adenocarcinoma, cholangiocarcinoma, appendiceal cancer, and colon cancer and glioblastoma multiforme in combination with range of anti-cancer regimens. Lisata Therapeutics, Inc. was formerly known as Caladrius Biosciences, Inc. and changed its name to Lisata Therapeutics, Inc. in September 2022. The company was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
384.15K4.26%599.28K
Other Institutional Investors
719.58K7.99%1.12M
Public Companies & Retail Investors
7.91M87.75%12.34M
Total
9.01M100.00%14.06M

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Vanguard Capital Management, LLC3.64%327,801511
Vanguard Index Funds - Vanguard Morningstar Total Stock Market ETF2.12%191,371299

People Also Watch

1.9150
TENX
-1.29%
0.827
PDSB
-9.15%
14.92
RARE
-4.48%
8.575
CAPR
-8.19%
1.6450
BIVI
+0.92%

FAQ

What Is the Lisata Therapeutics (LSTA) Stock Price Today?

The Lisata Therapeutics stock price today is 1.4500 USD.

What Stock Exchange Does Lisata Therapeutics Trade On?

Lisata Therapeutics is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for Lisata Therapeutics?

The stock symbol for Lisata Therapeutics is "LSTA."

What Is the Lisata Therapeutics Market Cap?

As of today, Lisata Therapeutics market cap is 13.0700M USD.

What Is Lisata Therapeutics's Earnings Per Share (TTM)?

The Lisata Therapeutics EPS (TTM) is -1.6404.

When Is the Next Lisata Therapeutics Earnings Date?

Lisata Therapeutics will release its next earnings report on Nov 05, 2026.

From a Technical Analysis Perspective, Is LSTA a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Lisata Therapeutics Stock Split?

Lisata Therapeutics has split 6 times.

How Many Employees Does Lisata Therapeutics Have?

Lisata Therapeutics has 21 employees.

What is the current trading status of Lisata Therapeutics (LSTA)?

As of Sep 23, 2026, Lisata Therapeutics (LSTA) is trading at a price of 1.4500 USD, with a previous close of 1.4800 USD. The stock has fluctuated within a day range of 1.4000 USD to 1.5000 USD, while its 52-week range spans from 0.9875 USD to 5.0700 USD.

What Is the LSTA Premarket Price?

LSTA's last pre-market stock price is 1.4600 USD. The pre-market share volume is 40.0000, and the stock has decreased by -0.0200, or -1.3500%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2026 - Fusion Media Limited. All Rights Reserved.